Aveo Oncology and Bristol Myers Squibb are collaborating on a phase III clinical trial to evaluate Fotivda (tivozanib) in combination with Opdivo (nivolumab) in patients with advanced relapsed or refractory renal cell carcinoma following prior immunotherapy exposure.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe